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Abstract
Background: Inflammatory Bowel Disease (IBD) is marked with chronic inflammation of intestinal epithelium
driven by oxidative stress. Traditional treatments with plant extracts gained renewed interest due to their ability to
ameliorate the multi factorial conditions like inflammation. We investigated the beneficial effects of Withania
somnifera in Trinitro Benzyl Sulfonic Acid (TNBS) induced experimental IBD through a rectally applicable
formulation.
Methods: The study included (i) preparation of gel formulation from aqueous Withania somnifera root extract
(WSRE), (ii) biochemical assays to determine its performance potential, (iii) testing of formulation efficacy in TNBS-
induced IBD rat model, and (iv) histo-patholgical studies to assess its healing and muco-regenerative effect in IBD-
induced rats. For this purpose, concentration dependant antioxidant activity of the extracts were evaluated using
biochemical assays like (a) inhibition of lipid peroxidation, (b) NO scavenging, (c) H2O2 scavenging, and (d) ferric
reducing power assay.
Results: The extract, at 500 μg/ml, the highest concentration tested, showed 95.6% inhibition of lipid peroxidation,
14.8% NO scavenging, 81.79% H2O2 scavenging and a reducing capacity of 0.80. The results were comparable with
standard antioxidants, ascorbic acid and curcumin. WSRE treatment positively scored on histopathological
parameters like necrosis, edema, neutrophil infiltration. The post treatment intestinal features showed restoration at
par with the healthy intestine. In view of these results, gel formulation containing an aqueous extract of W.
somnifera, prepared for rectal application was tested for its anti-inflammatory activity in TNBS-induced rat models
for IBD. Commercially available anti-inflammatory drug Mesalamine was used as the standard in this assay.
Conclusions: Dose of the rectal gel applied at 1000 mg of WSRE per kg rat weight showed significant muco-
restorative efficacy in the IBD-induced rats, validated by histo-pathological studies.
Background
Withania somnifera (Dunal), also known as Ashwa-
gandha, is an important member of family Solanaceae,
utilized as a medicine for more than 2500 years in
Indian medicinal classic “Ayurveda” [1]. Roots of this
plant are considered most active for therapeutic
purposes by virtue of significant accumulation of active
constituents, withanolides [2]. Several withanolides with
cyclooxygenase inhibitory and lipid peroxidation inhibi-
tory activity were isolated from leaves and fruits of
W. somnifera [3,4], besides anti-inflammatory [5], anti-
tumor [6] and antioxidant [7] activities. Immunomodu-
latory role of W. somnifera roots and anti-inflammatory
activity using adjuvant-induced arthritic rat models was
also demonstrated [8,9]. Luvone et al [10] had observed
that methanolic extracts of W. somnifera roots turns-on
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sion by acting at transcriptional level resulting in
increased production of NO by macrophage, which was
attributed to immunomodulatory and anti-inflammatory
activity. Considering the various biological activities,
roots of W. somnifera can potentially be utilized for the
effective treatment of various inflammatory conditions.
Inflammatory bowel disease (IBD) encompasses (i)
various conditions that result in chronic inflammation
of small and/or large intestine, alike in young, adults
and old, (ii) Ulcerative Colitis (UC), characterized by
chronic mucosal and sub-mucosal inflammation of large
intestine and rectum and (iii) Crohn’s Disease (CD),
which is chronic transmural inflammation of all/any
part of the gastro-intestinal tract involving mucosa, sub-
mucosa, muscular and connective tissue [11]. However,
IBD, UC and CD are considered together because of
similarities in their characteristics, pathology, complica-
tions, investigations, and treatment [12].
Etiology of IBD largely remains unknown [13]; how-
ever, development of tissue injury is attributed largely
to distorted immune system and reactive oxygen species
(ROS) [14]. Sustained production of reactive oxygen
and nitrogen species is due to dysfunction of immune
system is believed to play an important role in the
development of intestinal colon injury [15]. It is there-
fore, logical to treat this disorder by controlling oxida-
tive stress. Logically, antioxidant chemicals have been
the main therapeutic strategy in IBD for last 50 years
[16]. The popular treatment of IBD involves use of (a)
5-aminosalicylate based compounds, which are potent
ROS scavengers [17], (b) broad spectrum antibiotics, (c)
steroids and immuno-suppressants. These drugs are
typically associated with side effects like nausea, anor-
e x i a ,d i z z i n e s s ,h e a d a c h e ,c y t o p e n i a ,f e v e r ,m y a l g i a ,
abnormal liver function, pleropericarditis, renal insuffi-
ciency and pulmonary toxicity. Plants are considered to
be a goldmine to tackle complex inflammatory condi-
tions with minimum of side effects. The effective herbs
with antioxidant activity have been recently reviewed
[18]. Numbers of reports are available on anti-inflam-
matory activities of plant-derived crude extracts or com-
pounds derived from different plants. For example,
curcumin has been widely investigated for the treatment
of experimental colitis to decrease inflammation in ther-
apeutic dosages [19-22]. Similarly, formulation contain-
ing a mixture of four herbal drugs (Aegle marmeloes,
Coriandrum sativam, Cyperus rotundus and Vetiveria
zinzaniods) showed significant inhibitory activity com-
parable with the standard drug prednisolone [12]
against IBD induced in experimental animal models. It
has become, therefore, imperative to search for safer
alternative strategies that modulate the entire inflamma-
tory pathway.
Withania somnifera is a unique plant where a wide
range of activities has been demonstrated including
antagonism with several pro-inflammatory factors and
immunomdulation. In Ayurveda, enema of W. somnifera
water extract is prescribed for intestinal ulcers, irritable
bowel and rectal bleeding. All these attributes encour-
aged us to investigate its usefulness in the treatment of
IBD [23]. Ours is the first report where aqueous extract
of W. somnifera roots was assessed in Trinitro Benezyl
Sulfonic Acid (TNBS) induced IBD in rat model, using
formulation designed for rectal application. Mucosal
adhesion of the formulation facilitated precise applica-
tion of the extract on intestinal lesions.
Methods
Plant material and extract preparation
Authenticated roots of W. somnifera were procured
from Green Pharmacy, Pune. Its aqueous extract was
prepared by suspending 15 gm root powder in 100 ml
d i s t i l l e dw a t e r ,f o l l o w e db y shaking (150 rpm, at 60°C,
for 24 h). The extract was filtered and clear suspension
utilized for the antioxidant assays. Standardization of
the extract was done by HPTLC method for quantifica-
tion of Withanolide D using standard lab protocol.
Antioxidant assays
Five different biochemical assays were undertaken to
assess the antioxidant activity of W. somnifera aqueous
roots extract (WSRE)
1. Anti-lipid peroxidation activity
Anti-lipid peroxidation potential of WSRE was deter-
mined by estimating the inhibition of thiobarbituric acid
reactive species (TBARS). Lipid peroxidation was
initiated by adding 100 μlo f1m Mf e r r i cc h l o r i d ei n
10% w/v colon tissue homogenate. Malonyldialdehyde
(MDA) generated by the oxidation of polyunsaturated
fatty acids upon reaction with two molecules of thiobar-
bituric acid (TBA) yielded a pink red complex, which
was measured at 532 nm, from which % inhibition of
lipid peroxidation by WSRE was calculated. In practice,
mixtures containing 0.5 ml of tissue homogenate, 1 ml
0.15 M KCl and 0.5 ml different concentrations of
WSRE were prepared. Lipid peroxidation was initiated
by adding 100 μl of 1 mM ferric chloride. Incubated at
37°C for 30 min. The reaction was stoped by adding 2
ml ice-cold 0.25 N HCl (containing 15% trichloroacetic
acid (TCA), 0.38% TBA and 0.2 ml 0.05% butylated
hydroxyl toluene (BHT)). The reaction mixture was
heated at 80°C for 60 min, cooled, centrifuged (5000 g
≈6900 rpm, 15 min). Absorbance of the supernatant was
measured at 532 nm against a blank, which contained
all reagents except colon homogenate and WSRE. Iden-
tical experiments were performed to determine the nor-
mal (without drug and FeCl3) and induced (with the
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tage of anti-lipid peroxidation effect (%ALP) was calcu-
lated by the following formula [24].
%ALP = [AFecl3 − Atest./AFecl3 − ANormal] × 100
Where, AFeCl3: Absorbance of FeCl3,A Normal: Abso-
bance of control reaction,
Atest.: Absorbance of test reaction
2. Nitric oxide (NO) scavenging activity
Nitric oxide radical inhibition was estimated using
Griess-Illosvoy reaction principle. In this protocol, a
reaction mixture (6 ml) containing sodium nitroprusside
(10 mM, 2 ml), phosphate buffer saline (PBS) (0.5 ml)
and different concentrations of extract or standard solu-
tion was prepared. A reaction control without test com-
pound but equivalent amount of methanol was
maintained. Incubation was carried out at 25°C for 150
min, followed by treating 0.5 ml of the reaction mixture
with 1 ml Griess reagent A. In the next step, 1 ml of
Griess reagent B was added and incubated at 25°C for
60 min. Absorbance was measured at 540 nm. The %
inhibition was calculated using the formula [25].
%Inhibition = [(Acont − Atest)/(Acont)] × 100
Where Acont - absorbance of the control reaction
Atest - absorbance of reaction with the extract.
3. Hydrogen peroxide scavenging activity
Ability of the extract to scavenge H2O2 was determined
as per Ruch et al [26]. A solution of H2O2 was prepared
in PBS (pH 7.4) and its concentration determined spec-
trophotometrically. The reaction mixture (0.9 ml) con-
taining extract (0.3 ml) and H2O2 (0.6 ml each) in PBS
were incubated at ambient temperature for 10 min and
its absorbance at 260 nm was determined 10 min later
against a blank solution containing PBS without H2O2.
The % H2O2 scavenging of both, the extract and stan-
dard were calculated as follows:
H2O2 Scavenged(%) =[ (Acont − Atest)/(Acont)] × 100
Where, A cont.: Absorbance of control reaction, A test:
Absorbance of test reaction.
4. Evaluation of the reducing power
The reducing power of the extract was measured by the
transformation of Fe
3+ to Fe
2+ in the presence of differ-
ent concentrations of extract at 700 nm as per Mau
[27]. It involved mixing (a) 1 ml aliquot of different con-
centrations of WSRE (250-2500 μg/ml) with 2.5 ml
phosphate buffer (pH 6.8) and 2.5 ml potassium ferri-
c y a n i d e ,( b )i n c u b a t i n gi ta t5 0 ° Cf o r2 0m i n ,( c )a r r e s t -
ing the reaction by addition of 2.5 ml TCA (d)
centrifuging at 3000 rpm for 10 min, (e) taking 2.5 ml
supernatant, diluting with 2.5 ml distilled water, (f) add-
ing 0.5 ml of FeCl3 solution, and (g) measuring
absorbance at 700 nm. Increased absorbance of the
reaction mixture indicates increased reducing power.
Induction of experimental colitis
The animal experimental procedures were in accordance
with the regulation of institutional animal ethical com-
mittee, Poona College of Pharmacy, Bharati Vidyapeeth
University, (CPCSEA/47/2007-08). Wistar rats weighing
approximately 200-250 g each of either sex were distrib-
uted in four different groups (n = 6), i.e. healthy control,
negative control, positive control and test group were
housed in institutional animal house with controlled
temperature (25°C). TNBS/ethanol induced colitis in the
rat was established according to Elson et al [28]. After
overnight fasting, each rat was lightly anaesthetised with
diethyl ether, and a polyethylene cannula (4 mm dia-
meter) was inserted into the lumen of the colon and
advanced so that its tip was 6-8 cm proximal to the
anus. Initially, each rat was lavaged with 2 ml of saline
for enema followed by manual palpation of the abdomen
to remove the fecal matter, if any. Next, TNBS (100 mg/
kg of rat weight) dissolved in 50% ethanol (v/v) was
instilled into the colon lumen (only 0.25 ml) through
the rubber catheter, and the rat was maintained in a
head-down position for 20 seconds to limit the expul-
sion of solution. From the fourth day up to 14
th day
treatment was given by rectal administration of thermo-
reversable gel. Animals were maintained on water and
diet ad libitum through out.
Preparation of gel for rectal application
The gel preparation involved (a) use of sufficient
amount of pluronic F127 to yield desired 20 (% w/w)
gel, slowly added to cold (5°C) water with constant stir-
ring, and (b) refrigeration of dispersion until a clear
solution was formed. Concentration of WSRE was main-
tained such as to deliver 1 gm/kg body weight of the
IBD-rats per day (effective concentration of withanolide
D in the formulation was 0.0336% w/w) [29].
Assessment of severity of colitis
At the end of the experiments, rats were sacrificed by
cervical dislocation, the colon excised, opened longitud-
inally, and washed in saline. Macroscopic damage was
assessed on the basis of semi-quantitative scoring system
[30], which takes into account the area of inflammation
and presence/absence of ulcers as described by Ukil et
al [20] (No ulcer, no inflammation: 0; No ulcer, local
hyperemia: 1; Ulceration without hyperemia: 2; Ulcera-
tion and inflammation at one site only: 3; Ulceration
and inflammation at two or more sites: 4; and Ulcera-
tion extending more than 2 cm: 5). A 10 cm segment of
colon was excised and weighed as an increase in weight
is seen after induction of colitis. Further, these weights
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about weight recovery and malondialdehyde levels deter-
mined in each tissue, which served as an indicator of
lipid peroxidation.
Microscopic assessment of colitis
Histo-pathological studies of the colon were carried out
at Local Pathology Laboratory, by an expert cyto-histo-
pathologist by staining the sections with haematoxylin
and eosin and taking their colored microscopic images,
with resolution 10X-45X using a trinocular camera.
Statistical analysis
Results are expressed as mean ± standard deviation of n
observations. Analysis of variance (P < 0.05) to deter-
mine the statistical significance of inter-group compari-
sons, was considered statistically significant.
Macroscopic and microscopic scores for colon erosion
for the W. somnifera -pretreated groups were compared
against those for the TNBS-treated group with a one-
way ANOVA and Tukey test.
Results
Antioxidant potential of aqueous extracts, determined
biochemically using various assays, exhibited the follow-
ing profiles.
Anti-lipid peroxidation activity
Inhibitory effects of ascorbic acid and WSRE in the con-
centration range 100 to 500 μg/ml, on TBARS formed
in rat colon induced by FeCl3 in vitro were studied. It
w a sl o w e s t( 1 2 . 6 7 % )a t1 0 0μg/ml WSRE and gradually
increased to 95.59% at 500 μg/ml, thus showing increase
in the activity with an increase in the concentration. In
ascorbic acid, anti-lipid peroxidation inhibition activity
at 100 μg/ml was far higher (85.71%) than WSRE; it was
six fold more than that of WSRE at the same concentra-
tion. It showed 99.97% inhibition of lipid peroxidation at
500 μg/ml (Table 1). Unpaired T-test showed significant
P value of 0.0411.
Nitric oxide scavenging activity
WSRE at 100 μg/ml concentration showed 10.55% NO
scavenging activity, which increased to 14.30 at 200 μg/
ml, beyond which no significant increase was noted with
further increase in concentrations (IC50 = 58.70 μg/ml)
(Table 1). Curcumin, used as a positive control at 50
μM concentration showed 11.79% NO scavenging,
almost comparable with that by WSRE.
Hydrogen peroxide scavenging activity
Ascorbic acid, used as a standard, at 10 μg/ml concen-
tration showed 98.95% inhibition (data not shown in
table). Hydrogen peroxide scavenging activity of the
extract was concentration-dependent; about 59.84%
H2O2 scavenging activity at 100 μg/ml concentration
increased up to 81.79% as a function of increase in the
concentration of the extract to 500 μg/ml (Table 1),
indicating that aqueous extracts of roots of W. somnifera
are good scavenger of peroxide radicals.
Evaluation of the reducing potential
As expected from the literature, the WSRE exhibited
significant reductive potential towards Fe
3+ to result
into Fe
2+. It was about 0.5 At 100 μg/ml concentrations,
which was at par with the standard ascorbic acid.
Further, it showed a clear dose dependent increase in
reducing power (Table 1).
Pharmacological screening
Rectal gel formulation was tested for its gelation and gel
melting temperatures after addition of the extract.
Bioadhesive strength of the formulation was measured
on goat colon (Data not shown).
Malonyldialdehyde (MDA) levels were measured as an
indicator of lipid peroxidation. In rats without any treat-
ment (healthy control) average MDA levels were 11.63,
far lower as compared to those in rats subjected to
TNBS enema and no drug treatment (22.85), whereas
rats treated with W. somnifera formulation (WSREF)
(test control) showed significant decrease (18.15) in
MDA levels, comparable with the mesalamine (standard
drug) treated rats (18.66) (Table 2).
Macroscopic and histological evaluation
TNBS enema resulted in pronounced hemorrhagic and
ulcerative lesions in the colon as observed after induc-
tion up to 8 days. Macroscopic examination of the
Table 1 Comparative Antioxidant Free radical scavenging and anti-inflammatory activity of Withania somnifera
% LPO Inhibition % NO Scavenging % H2O2 Scavenging Reducing power
Conc. (μg/ml) Withania somnifera Ascorbic acid Withania somnifera Withania somnifera Withania somnifera Ascorbic acid
100 12.67 ± 0.83 85.71 ± 0.72 10.55 ± 0.97 59.84 ± 0.79 0.4996 ± 1.34 0.4177 ± 1.53
200 51.73 ± 1.26 91.54 ± 0.98 14.30 ± 0.86 63.52 ± 0.85 0.5247 ± 1.21 0.5647 ± 1.04
300 65.02 ± 1.13 96.05 ± 0.86 14.41 ± 0.93 73.59 ± 0.98 0.6137 ± 0.95 0.6804 ± 1.02
400 75.70 ± 1.23 99.09 ± 0.84 14.75 ± 0.96 76.30 ± 1.13 0.7053 ± 0.89 0.7106 ± 1.21
500 95.59 ± 0.56 99.97 ± 1.36 14.77 ± 1.13 81.79 ± 1.23 0.7972 ± 0.58 0.8090 ± 0.96
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mucosal lining and severe ulceration often indicated as
fecal occult blood. The histological features included (a)
transmural necrosis, (b) edema and (c) diffused leuco-
cytes infiltration of the sub-mucosa. Treatment of rats
with WSREF (0.5 ml daily, containing 1 g/kg body
weight) resulted in a significant decrease in the extent
and severity of the injury of large intestine as evidenced
by macroscopic damage score in Table 3 as well as his-
topathological assessment as in Figure 1. In healthy con-
trol (rats without any treatment), (i) intestinal crypts
were evenly spaced, dipping down unto muscularis and
(ii) lamina propria mucosae showed usual number of
lymphocytes, plasma cells as well as eosinophils (Figure
1a). In negative control (rats treated with TNBS only),
mucosa showed (i) ulceration, (ii) crypts were obligated,
(iii) lamina propria marked with edema and (iv) infiltra-
tion by eosinophils as well as neutrophils (Figure 1b),
while the test control (IBD induced rats treated with
WSREF) mucosa showed (i) normal crypts, and (ii)
lamina propria with usual number of mononuclear
inflammatory cells (Figure 1c). In positive control (IBD-
induced rats treated with mesalamine), mucosal crypts
showed slight distortion and both edema and lamina
propria, showed infiltration by neutrophils and eosino-
phils (Figure 1d).
The observed inflammatory changes of the large intes-
tine were associated with an increase in the weight of
colon (Figure 2) as well as significant decrease in the
body weight as compared to control rat (Figure 3). In
contrast, no significant increase in the colon weight was
found in the TNBS-treated rats on treatment with
WSRE and marketed formulation of mesalamine. More-
over, treatment with these formulation dosages signifi-
cantly reduced the loss in body weight, which correlated
well with the amelioration of colon injury. The above
data was subjected to statistical treatment by Tukey test
and p values were obtained. The p value < 0.001 for W.
somnifera and standard group was highly significant;
suggesting that rats treated with W. somnifera rectal gel
formulation showed marked recovery.
Discussion
IBD is a common gastro-intestinal disorder marked with
chronic inflammation of intestinal epithelium, damaging
mucosal tissue and manifests into several intestinal and
extra-intestinal symptoms, mainly related to oxidative
stress, inflammation and autoimmune type.
TNBS-induced model is an experimental model of
Th 1, like gut inflammation, mimics human Crohn’s
Disease and is widely used to investigate IBD [28].
TNBS enema develops hapten-induced delayed type
hypersensitivity and results in the development of
chronic colitis involving granuloma with infiltration of
inflammatory cells in all layers of the intestine. This is
due to TNBS-induced over expression of IL-12, IFN-g
and IL-2, which supports the study that inducible coli-
tis is due to Th-type 1 response [31]. Ilan et al. [32]
studied the involvement of immune system in the
pathogenesis of IBD after observing the similarities
between human disease and TNBS-induced colitis.
Their study revealed that IBD could be considered as
an imbalance between pro-inflammatory and anti-
inflammatory mediators. Monocytes/macrophages,
polymorphonuclear leucocytes (PMNs) and endothelial
Table 2 Malondialdehyde levels as an indicator of lipid peroxidation
Lipid peroxidation in rat intestine Healthy control Positive control Negative control WSAE* treated
1 11.65 18.52 23.68 17.79
2 12.42 17.26 24.3 19.03
3 9.63 19.39 22.34 19.66
4 13.53 18.3 21.76 16.68
5 12.1 19.92 22.88 18.52
6 10.46 18.59 22.17 17.23
AVG
# 11.63 18.66 22.85 18.15
STDV** 1.401 0.920 0.969 1.125
Abbreviation: * = Withania somnifera aqueous extract
# = Average
** = Standard deviation
Table 3 Effect of various treatments on macroscopic
score analysis
Group name Score rate N* Mean
012345
HC** 5100006 0.16
N C 0112206 2.83
T C 0321006 1.60
P C 0222006 2.00
**HC: Healthy control; NC: colitis control; TC: Test control; PC: Positive control;
*n: number of rats per group.
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their activation forces them to aggregate and infiltrate
t h et i s s u e ,w h e r et h e yu n d e r go respiratory burst, which
increases their oxygen use resulting into oxidative
damage to the tissue and triggers the production of
pro-inflammatory cytokines, ROS and other mediators
of inflammation [33].
Initiation and perpetuation of inflammatory cascade by
ROS causes subsequent tissue damage through the acti-
vation of nuclear factor kappa B (NF-kB), which is a
ubiquitous transcription factor involved in the regulation
of several genes in immune and inflammatory responses
[34]. Oxidants are potent activators of NF-kB while the
groups of structurally diverse anti-oxidants of herbal ori-
gin are capable of inhibiting NF-kB activation [35].
Human body has its own anti-oxidant defense system,
Figure 1 Histopathological features of colon section of a). healthy control rat, b). rat with TNBS treatment, c). rat with TNBS +WSREF
treatment, d). rat with TNBS+Mesalamine treatment.
Figure 2 Change in colon weight as a function of period of
treatment. HC: Healthy control, CC: Colitis control, WS: WSREF
treated, STD: Standard (Mesalamine) control.
Figure 3 Change in rat weight as a function of period of
treatment.
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catalases and glutathione peroxidases. However, this
enzymatic anti-oxidant defense system is often not suffi-
cient, leading to increased free radicals and oxidative
damage ultimately resulting in severe inflammation and
cell death [36].
The gastro-intestinal tract is a major site of generation
of pro-oxidants, whose production is primarily due to
t h ep r e s e n c eo fp l e t h o r ao fm i c r o b e s ,f o o di n g r e d i e n t s
and interaction between immune cells. Not surprisingly,
ROS has been implicated in the initiation and perpetua-
tion of inflammatory disorders and pathogenesis of IBD.
In one study, saliva of IBD patients were studied as an
indicator of existence of oxidative and nitrosative stress.
Excessive NO as well as higher levels of epidermal
growth factor were found associated with the disease
[37]. Similarly increased ROS in colon mucosa of UC
patients was demonstrated [38,39] and animal model
exhibits increased oxidation and lipid peroxidation dur-
ing initiation of colitis [40].
W. somnifera extract seems to be a balanced combina-
tion of biologically active ingredients as demonstrated
by several workers. The cyto-protective and anti-inflam-
matory activity has protected experimental animals
against the induced diseases. Antibacterial activity
demonstrated by W. somnifera may also have significant
role to play in IBD, especially for combating against the
intestinal opportunistic pathogens known to play an
important role in pathogenesis of IBD. Carminative and
anti-diarrheal activity of W. somnifera may also be use-
ful in restoring the disturbed gastro-intestinal mobility.
Anti-oxidant activity is thought to play a central role in
preventing inflammation as well restoration of mucosal
lining. In the present study, aqueous extracts of W. som-
nifera roots have shown an excellent anti-oxidant activ-
ity, which is in total agreement with study carried out
by Bhatnagar et al [41]. W. somnifera exhibits inhibition
of (a) cyclooxygenase (b) activation of NF-kB induced
inflammatory markers (like tumor necrosis factor alpha
(TNF-aalpha) and interleukins) [42]. The withanolides
constituting active ingredients of W. somnifera roots
shows promising antibacterial, anti tumor, immunomo-
dulating and anti-inflammatory properties [9].
Anti-ulcer activity of methanolic extract of W. somni-
fera and its action against stress pyloric ligation induced
gastric ulcer in rats has been reported [41]. Treatment
with W. somnifera extract (100 mg/kg/day p.o.) for 15
days, significantly reduced volume of gastric secretion,
free total acidity and ulcer index as compared to control
group. Significant increase in total carbohydrates (TC)
and its ratio to total protein (TP) was also observed,
without significant change in total proteins. A significant
increase in antioxidant enzymes (viz. catalase, superox-
ide dismutase (SOD)) and decrease in malondialdihyde
(MDA) was observed. Increased MDA levels after TNBS
enema decreased upon treatment with W. somnifera for-
mulation (Table 2). W. somnifera extract was found
effective antiulcerogenic agent, comparable of ranitidine
hydrochloride [41]. Treatment with W. somnifera for-
mulation has shown decrease in macroscopic scores for
the IBD. Histopathology examination of W. somnifera
extract treated group revealed less damage compared to
healthy animals (control group). Mesalamine treatment
compared to W. somnifera f o r m u l a t i o nh a ss h o w ns i g -
nificant and comparable protection in the rats in our
study as revealed by the decreased colon weight and
better gain in body weight. In the light of above proper-
ties, WSREF can potentially cure local inflammation,
modulate immune system and can be a logical choice in
relieving IBD symptoms. Administration of Iranian folk
herbal medicines Ziziphora clinopoides and Teucrium
persicum were reported to boost body’s antioxidant
mechanism such as SOD and catalase, with concomitant
decrease in pro-inflammatory factors like TNF-aalpha,
IL-1b. These studies suggest potential dexterity of folk
medicine in management of disease like IBD where free
radicals and inflammation is the major pathophysiology
[43,44].
Success of herbal extracts in repairing tissue damage
in experimental colitis could be enhanced by changing
the route of administration. Several plant extracts have
been reported beneficial in IBD, however, to our knowl-
edge there is no report on a rectally applicable formula-
tion. The pluronic rectal gel formulation impregnated
with WSRE is in liquid form that is easy to apply as
enema. At body temperature, it turns into a gel, which
covers the rectum surface and due to its mucoadhesive
property it forms a layer that persist and slowly release
WSRE at the lesions in the rectum. This feature
enhanced the beneficial effects of WSRE and resulted in
reduced inflammation, faster healing and mucorestora-
tion as revealed by the microscopic observations. Not all
the extracts with good antioxidant activity could be ben-
eficial in IBD. Harputluoglu et al [16] investigated oral
application of Gingko biloba extract in acetic acid-
induced colitis. Despite of an excellent antioxidant activ-
ity and antagonistic activity against platelets activating
factor, (known to play a key role in pathogenesis of
IBD), the extract failed to show noticeable recovery in
experimental colitis. Based on the present data, topical
application of aqueous extract of W. somnifera roots is
strongly recommended in the treatment of distal colitis,
especially for an early recovery in the damaged tissue.
This data also substantiate the traditional way of treat-
ing colitis patients with enema of Ashwagandha extract.
Detailed molecular study to identify the precise nature
of active molecules will further assist in understanding
their mechanism of action.
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This study affirms antioxidant potential of aqueous
extract of roots of Withania somnifera and it’s utility to
ameliorate inflammation, which is the key pathology in
IBD. The topical application in the form of rectal gel
formulation proved to be as effective as the mesalamine
treatment. In addition, WSREF showed marked muco-
restoration and provides alternative strategy of practical
significance for the treatment of Inflammatory Bowel
Disease.
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